Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 9/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 6/20 | 0.41 |
| ▸ | ANPEP | P15144 | 1/20 | 0.40 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3462484 | 1.00 | CA1 (0.42) | CA1CA2CA7CTSKATM | |
| SCHEMBL2329376 | 1.00 | CA1 (0.42) | CA1CA2CA7CTSKATM | |
| SCHEMBL5691699 | 0.91 | CA1 (0.46) | CA1CA2CA7CTSKATM | |
| SCHEMBL25319084 | 0.89 | CA1 (0.41) | CA1CA2CA7CTSKATM | |
| SCHEMBL25319090 | 0.89 | CA1 (0.41) | CA1CA2CA7CTSKATM | |
| SCHEMBL20276859 | 0.87 | CTSK (0.47) | CA1CA2CA7CTSKATM | |
| SCHEMBL4671387 | 0.87 | CYP2D6 (0.45) | CA1CA2CA7CTSKATM | |
| SCHEMBL13964494 | 0.87 | CA1 (0.42) | CA1CA2CA7CTSKATM | |
| SCHEMBL15376153 | 0.87 | CTSK (0.47) | CA1CA2CA7CTSKATM | |
| SCHEMBL2104058 | 0.87 | CYP2D6 (0.45) | CA1CA2CA7CTSKATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11981661-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2024-05-14 | — | — | US | disclosed |
| CN-116744927-A | Fused heterocyclic derivatives and their use in the treatment of HBV infection | 杨森科学爱尔兰无限公司 | 2023-09-12 | — | — | CN | disclosed |
| EP-4208456-A1 | HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2023-07-12 | — | — | EP | disclosed |
| CN-115666553-A | TLR2 modulator compounds, and pharmaceutical compositions and uses thereof | 轴向治疗公司 | 2023-01-31 | — | — | CN | disclosed |
| US-10450325-B2 | Processes of preparing a JAK1 inhibitor and new forms thereto | INCYTE CORPORATION (US) | 2019-10-22 | — | — | US | disclosed |
| US-20180099978-A1 | PROCESSES OF PREPARING A JAK1 INHIBITOR AND NEW FORMS THERETO | INCYTE CORPORATION | 2018-04-12 | — | — | US | disclosed |
| US-9802957-B2 | Processes of preparing a JAK1 inhibitor and new forms thereto | INCYTE CORPORATION (US) | 2017-10-31 | — | — | US | disclosed |
| US-9725450-B2 | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2017-08-08 | — | — | US | disclosed |
| EP-3137471-A1 | PROCESSES OF PREPARING A JAK1 INHIBITOR AND NEW FORMS THERETO | Incyte Corporation (US) | 2017-03-08 | — | — | EP | disclosed |
| US-20160039822-A1 | HALOARYL SUBSTITUTED AMINOPURINES, COMPOSITIONS THEREOF,AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2016-02-11 | — | — | US | disclosed |
| US-20020193348-A1 | Benzamidine derivatives | AJINOMOTO CO., INC. (JP) | 2002-12-19 | — | — | US | disclosed |
| EP-1236735-A1 | BENZAMIDINE DERIVATIVES | Ajinomoto Co., Inc. (JP) | 2002-09-04 | — | — | EP | disclosed |
| US-20020107290-A1 | Benzamidine derivative | AJINOMOTO CO., INC. (JP) | 2002-08-08 | — | — | US | disclosed |
| US-6410538-B2 | ANTICOAGULANT OR AN AGENT FOR TREATING OR PREVENTING THROMBI OR EMBOLI | AJINOMOTO CO., INC. (JP) | 2002-06-25 | — | — | US | disclosed |
| US-20020048588-A1 | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors | CORIXA CORPORATION | 2002-04-25 | — | — | US | disclosed |
| US-20010056123-A1 | Anticoagulant or an agent for treating or preventing thrombi or emboli | AJINOMOTO CO., INC (JP) | 2001-12-27 | — | — | US | disclosed |
| US-6303347-B1 | VACCINES | CORIXA CORPORATION | 2001-10-16 | — | — | US | disclosed |
| EP-1086946-A1 | BENZAMIDINE DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2001-03-28 | — | — | EP | disclosed |
| EP-0505467-A1 | PHARMACOLOGICALLY ACTIVE AMIDE CARBOXYLATE DERIVATIVES | Astra Pharmaceuticals Limited (GB) | 1992-09-30 | — | — | EP | disclosed |
| WO-1991008737-A2 | PHARMACOLOGICALLY ACTIVE AMIDE CARBOXYLATE DERIVATIVES | FISONS PLC (GB) | 1991-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10450325-B2 | Processes of preparing a JAK1 inhibitor and new forms thereto | JAK1, JAK2, JAK3 | CA1 4464/4885CA2 4653/4885CA7 4453/4885 |
| US-20020107290-A1 | Benzamidine derivative | SERPINE1, SERPINC1, TFPI | CA1 3403/4885CA2 3566/4885CA7 3132/4885 |
| US-20020193348-A1 | Benzamidine derivatives | SERPINC1, SERPINE1, TFPI | CA1 3061/4885CA2 2678/4885CA7 2197/4885 |
| US-20010056123-A1 | Anticoagulant or an agent for treating or preventing thrombi or emboli | SERPINC1, SERPINE1, F2 | CA1 1471/4885CA2 1711/4885CA7 1748/4885 |
| US-20020048588-A1 | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors | DNPEP, CD68, MGAT3 | CA1 2584/4885CA2 1308/4885CA7 2194/4885 |
| US-11981661-B2 | Heterocyclic compounds | CBR3, BRIX1, CCNY | CA1 3624/4885CA2 3696/4885CA7 1923/4885 |
| US-20160039822-A1 | HALOARYL SUBSTITUTED AMINOPURINES, COMPOSITIONS THEREOF,AND METHODS OF TREATMENT THEREWITH | TPMT, MGMT, HPRT1 | CA1 3469/4885CA2 2652/4885CA7 3274/4885 |
| US-20180099978-A1 | PROCESSES OF PREPARING A JAK1 INHIBITOR AND NEW FORMS THERETO | JAK1, JAK2, JAK3 | CA1 4464/4885CA2 4653/4885CA7 4453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.